Revvity’s third quarter results were met with a significant negative reaction from the market, as investors focused on sluggish organic revenue growth and margin compression despite headline results aligning with Wall Street expectations. Management pointed to a strong performance in its Signals software and reproductive health businesses, with CEO Prahlad R. Singh highlighting that “our signals software business continued to perform extremely well, growing 20% organically,” and that “newborn screening again grew in the high single digits in the quarter.” However, challenges persisted, particularly in China’s diagnostics segment, where volumes remained under pressure, and lower life sciences reagent sales contributed to margin declines. Singh acknowledged these headwinds, noting the company remains focused on cost containment and cash flow generation.
Life sciences company Revvity (NYSE:RVTY) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 2.2% year on year to $698.9 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $2.86 billion at the midpoint. Its non-GAAP profit of $1.18 per share was 3.6% above analysts’ consensus estimates.
Shares of life sciences company Revvity (NYSE:RVTY)
fell 2.4% in the afternoon session after it reported third-quarter financial results that showed a drop in profits and margins, even as revenue grew.
Wall Street extended its record-setting streak on Monday, with major large-cap indices logging a third consecutive session of strong gains after a breakthrough in trade negotiations between Washington and Beijing.
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
Life sciences company Revvity (NYSE:RVTY) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 2.2% year on year to $698.9 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $2.86 billion at the midpoint. Its non-GAAP profit of $1.18 per share was 3.6% above analysts’ consensus estimates.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at research tools & consumables stocks, starting with Revvity (NYSE:RVTY).
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Washington D.C. – The Federal Reserve has sent clear signals of a continued dovish pivot, with Chair Jerome Powell indicating the likelihood of two additional quarter-point interest rate cuts before the close of 2025. This aggressive stance comes on the heels of a September rate reduction and is primarily driven
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
Washington D.C. – September 30, 2025 – Shares of Agilent Technologies (NYSE: A) experienced a significant upward movement today, closing strong amidst breaking news of a landmark drug-pricing agreement between the White House and pharmaceutical giant Pfizer (NYSE: PFE). This surge, echoing similar positive movements for other life sciences companies like
As of September 30, 2025, the financial markets are grappling with the implications of a landmark drug-pricing agreement between the White House and pharmaceutical giant Pfizer (NYSE: PFE), a move signaling a broader governmental push to significantly lower prescription drug costs. While such developments typically send ripples across the entire
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped the upside for healthcare stocks lately as the industry’s flat return over the past six months has trailed the S&P 500’s 18.3% gain.
